Regeneron Pharmaceuticals Inc

REGN Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of REGN by members of U.S. Congress

Politician Type Traded
Robert Bresnahan House / R Sale $1,001 - $15,000 Feb. 25, 2025
Julie Johnson House / D Sale $1,001 - $15,000 Feb. 12, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Jan. 24, 2025
Julie Johnson House / D Purchase $1,001 - $15,000 Jan. 15, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 29, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 19, 2024
Jonathan L. Jackson House / D Sale $15,001 - $50,000 Nov. 13, 2024
Jonathan L. Jackson House / D Sale $1,001 - $15,000 Nov. 01, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Oct. 23, 2024
Greg Landsman House / D Sale $1,001 - $15,000 Oct. 15, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Jul. 01, 2024
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Apr. 04, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Feb. 08, 2024
Jonathan L. Jackson House / D Purchase $1,001 - $15,000 Jan. 17, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 13, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Aug. 21, 2023
Greg Landsman House / D Purchase $1,001 - $15,000 Aug. 11, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jul. 11, 2023
Jonathan L. Jackson House / D Purchase $15,001 - $50,000 Jun. 23, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun. 22, 2023
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Apr. 03, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Mar. 06, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Oct. 19, 2022
Josh Gottheimer House / D Purchase $1,001 - $15,000 Sep. 12, 2022
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Mar. 30, 2022
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Feb. 28, 2022
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Sep. 17, 2021
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jul. 21, 2021
Josh Gottheimer House / D Sale $1,001 - $15,000 Jul. 01, 2021
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jun. 17, 2021
Josh Gottheimer House / D Sale $1,001 - $15,000 May. 17, 2021
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Mar. 29, 2021
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jan. 11, 2021
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Dec. 22, 2020
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec. 11, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Aug. 14, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Jul. 10, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 May. 27, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 May. 20, 2020
Dean Phillips House / D Sale $1,001 - $15,000 May. 13, 2020
Dean Phillips House / D Sale $1,001 - $15,000 Apr. 02, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Feb. 20, 2020
Mikie Sherrill House / D Purchase $1,001 - $15,000 Jan. 15, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Dec. 12, 2019
Josh Gottheimer House / D Purchase $1,001 - $15,000 Nov. 01, 2019
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep. 20, 2019
Thomas R. Suozzi House / D Sale $50,001 - $100,000 Sep. 16, 2019
Dean Phillips House / D Purchase $1,001 - $15,000 Sep. 11, 2019
Thomas R. Suozzi House / D Sale $1,001 - $15,000 Aug. 21, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Aug. 14, 2019
REGN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
REGN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
REGN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by REGN's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $400,000 Apr 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
  • $400,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $430,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Jan 20, 2022 Issue: None
  • $360,000 Oct 20, 2021 Issue: None
  • $310,000 Jul 20, 2021 Issue: None
  • $330,000 Apr 20, 2021 Issue: None
  • $330,000 Jan 21, 2021 Issue: None
  • $480,000 Oct 20, 2020 Issue: None
  • $320,000 Jul 20, 2020 Issue: None
  • $370,000 Apr 20, 2020 Issue: None
  • $340,000 Jan 21, 2020 Issue: None
  • $180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
  • $300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
  • $240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
  • $130,000 Oct 20, 2016 Issue: Health Issues
  • $120,000 Jul 20, 2016 Issue: Health Issues
  • $50,000 Apr 19, 2016 Issue: Health Issues
  • $50,000 Jan 16, 2016 Issue: Health Issues
  • $50,000 Oct 20, 2015 Issue: Health Issues
  • $50,000 Jul 20, 2015 Issue: Health Issues
  • $60,000 Apr 20, 2015 Issue: Health Issues
  • $52,000 Jan 19, 2015 Issue: Health Issues
  • $50,000 Oct 20, 2014 Issue: Health Issues
  • $50,000 Jul 21, 2014 Issue: Health Issues
  • $50,000 Jan 22, 2014 Issue: Health Issues
  • $50,000 Oct 21, 2013 Issue: Health Issues
  • $40,000 Jul 22, 2013 Issue: Health Issues
  • $30,000 Apr 24, 2013 Issue: Health Issues
  • $30,000 Feb 02, 2013 Issue: Health Issues
  • $30,000 Oct 31, 2012 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

Revenue Breakdown

REGN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
REGN Income Statement
REGN Balance Sheet
REGN Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Anti-pcsk9 antibodies Apr. 08, 2025
  • Patent Title: Human antibodies to the human glucagon receptor (hgcgr) and methods of use thereof to lower blood glucose or ketone levels Apr. 08, 2025
  • Patent Title: Use of a vegf antagonist to treat angiogenic eye disorders Apr. 08, 2025
  • Patent Title: Genome-based methods for reducing cardiovascular risk Apr. 01, 2025
  • Patent Title: Tcra homing endonuclease variants Apr. 01, 2025
  • Patent Title: High confidence compound identification by liquid chromatography-mass spectrometry Mar. 25, 2025
  • Patent Title: Microchip capillary electrophoresis assays and reagents Mar. 25, 2025
  • Patent Title: Kelch domain containing 7b (klhdc7b) variants and uses thereof Mar. 25, 2025
  • Patent Title: Methods and compositions for therapeutic protein delivery Mar. 25, 2025
  • Patent Title: Nucleic acid molecules encoding bispecific anti-bcma x anti-cd3 antibodies Mar. 25, 2025
  • Patent Title: Humanized dipeptidyl-peptidase iv (dpp4) animals Mar. 25, 2025
  • Patent Title: Data pipeline Mar. 18, 2025
  • Patent Title: Microchip capillary electrophoresis assays and reagents Mar. 18, 2025
  • Patent Title: Anti-cd63 antibodies, conjugates, and uses thereof Mar. 18, 2025
  • Patent Title: Human antibodies to fel d1 and methods of use thereof Mar. 18, 2025
  • Patent Title: Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments Mar. 18, 2025
  • Patent Title: Genetically modified mouse with a humanized pnpla3 gene and methods of use Mar. 18, 2025
  • Patent Title: Protein a chromatography-electrospray ionization mass spectrometer Mar. 11, 2025
  • Patent Title: Systems and methods for chromatography use and regeneration Mar. 11, 2025
  • Patent Title: N-terminal scfv multispecific binding molecules Mar. 04, 2025
  • Patent Title: N-terminal scfv multispecific binding molecules Mar. 04, 2025
  • Patent Title: Online chromatography and electrospray ionization mass spectrometer Mar. 04, 2025
  • Patent Title: Sustained release formulations using non-aqueous membrane emulsification Mar. 04, 2025
  • Patent Title: Humanized il-6 and il-6 receptor Mar. 04, 2025
  • Patent Title: Eukaryotic cells comprising adenovirus-associated virus polynucleotides Feb. 25, 2025
  • Patent Title: Methods of treating decreased bone mineral density with cluster of differentiation 109 (cd109) inhibitors Feb. 25, 2025
  • Patent Title: Hydrophobic interaction chromatography for viral clearance Feb. 25, 2025
  • Patent Title: Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden Feb. 18, 2025
  • Patent Title: Cblb endonuclease variants, compositions, and methods of use Feb. 18, 2025
  • Patent Title: Systems and methods for producing a mixer Feb. 18, 2025
  • Patent Title: Auto-injector and related methods of use Feb. 18, 2025
  • Patent Title: Auto-injector and related methods of use Feb. 18, 2025
  • Patent Title: Taurine supplemented cell culture medium and methods of use Feb. 11, 2025
  • Patent Title: Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1) Feb. 04, 2025
  • Patent Title: Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (gpam) inhibitors Feb. 04, 2025
  • Patent Title: Antigen binding molecule formats Feb. 04, 2025
  • Patent Title: Compositions and methods for internalizing enzymes Feb. 04, 2025
  • Patent Title: Igg fc-il2-rα-il2 fusions and methods of use thereof Feb. 04, 2025
  • Patent Title: Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation Jan. 28, 2025
  • Patent Title: Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists Jan. 28, 2025
  • Patent Title: Adam6 mice Jan. 28, 2025
  • Patent Title: Anti-vegf protein compositions and methods for producing the same Jan. 21, 2025
  • Patent Title: Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein Jan. 21, 2025
  • Patent Title: Non-human animals comprising a humanized coagulation factor 12 locus Jan. 21, 2025
  • Patent Title: Use of lc-ms/ms to quantitate protein biomarkers Jan. 14, 2025
  • Patent Title: Retainer adapter assembly Jan. 14, 2025
  • Patent Title: Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer Jan. 07, 2025
  • Patent Title: Il10 agonists and methods of use thereof Jan. 07, 2025
  • Patent Title: Methods of treating skin cancer with histidine ammonia-lyase (hal) agonists Jan. 07, 2025
  • Patent Title: Antigen binding molecule formats Dec. 31, 2024
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

REGN News

Recent insights relating to REGN

CNBC Recommendations

Recent picks made for REGN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in REGN

REGN Analyst Ratings

REGN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
REGN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $REGN stock a Buy, Sell, or Hold?

  • What is the price target for $REGN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

REGN Top Shareholders
Shareholder
Shares Held
REGN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $REGN stock?

  • Who owns the most shares of $REGN stock?

  • What funds own $REGN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

REGN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view REGN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top